Experimental Neuroblastoma Therapy Overcomes Resistance in Mice

Researchers at St. Jude Children’s Research Hospital have reported encouraging results for a novel neuroblastoma immunotherapy that could address treatment resistance, a very common problem for this form of cancer. In a study published in Nature Communications , the research team reports how these tumors become resistant and developed a combination treatment that can effectively eliminate neuroblastoma and prevent relapse.

Neuroblastoma is a rare type of cancer impacting nerve tissue that primarily affects children under the age of five, often arising during fetal development driven by MYC oncogenes. The low number of mutations typically found in these tumors can severely limit the efficacy of immunotherapy approaches , such as checkpoint inhibitors, and the five-year survival